Human IL-17A&IL-17F Heterodimer Protein, Twin Strep&His Tag, low endotoxin (MALS verified)
Cat. No. ILF-H52W6
| Molecule | Cat. No. | Product Name | Species | Host | Structure | Purity | Activity | Size&Price |
|---|---|---|---|---|---|---|---|---|
| IL-17A & IL-17F | Human IL-17A&IL-17F Heterodimer Protein, Twin Strep&His Tag, low endotoxin (MALS verified) | Human | HEK293 | ![]() | MALSSDS-PAGE | $180.00 20ug | ||
| IL-17A & IL-17F | AvitagAIDD‑Ready ILF-H82W1 | Biotinylated Human IL-17A&IL-17F Protein, Avitag™,His Tag | Human | HEK293 | ![]() | SDS-PAGE | $415.00 25ug | |
| IL-17A & IL-17F | Mouse IL-17A&IL-17F Heterodimer Protein, His Tag (MALS verified) | Mouse | HEK293 | ![]() | MALSSDS-PAGE | $550.00 100ug |
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Sonelokimab | ALX-0761; MSB-0010841; M-1095 | Phase 3 Clinical | Ablynx Nv | Arthritis, Psoriatic; Hidradenitis Suppurativa; Psoriasis | Details |
| DMT-310 | DMT-310 | Phase 3 Clinical | Dermata | Acne Vulgaris; Rosacea | Details |
| ORKA-002 | ORKA-002; PR-029; ORKA-021 | Phase 2 Clinical | Paragon Therapeutics Inc | Arthritis, Psoriatic; Plaque psoriasis; Psoriasis | Details |
| PN-881 | PN-881 | Phase 1 Clinical | Protagonist Therapeutics Inc | Dermatitis; Psoriasis | Details |
| HY-1770 | HY-1770; HT-17; HT17; YF02; HT25; GH02; HY1770 | Phase 1 Clinical | Suzhou Pharmavan Co Ltd | Dermatitis, Atopic; Plaque psoriasis | Details |